CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson’s disease models
Authors:
Open Access
- 2 February 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 22 (1) , 1-23
Abstract
Parkinson’s disease (PD) is a progressive degenerative disease of the central nervous system associated with neuroinflammation and microglial cell activation. Chemokine signaling regulates neuron-glia communication and triggers a microglial inflammatory profile. Herein, we identified the neuronal chemokine CCL21 as a major cause of microglial cell imbalance through the CCR7 receptor pathway with therapeutic implications for PD. In humans, we found that CCL21 transcript expression was increased in dopaminergic neurons (DANs) of the substantia nigra in PD patients. CCL21 and CCR7 expressions were spatially associated with brain regional vulnerability to synucleinopathies, as well as with the expression of microglial activation, neuroinflammation, and degeneration-related genes. Also, in mouse models of PD, we showed that CCL21 was overexpressed in DANs in vivo and in vitro. Mechanistically, neuronal CCL21 was shown to regulate microglial cell migration, proliferation, and activation in a CCR7-dependent manner through both canonical (PI3K/AKT) and non-canonical (ERK1/2/JNK) signaling pathways. Finally, we demonstrated that navarixin, a clinically relevant chemokine inhibitor with high affinity for the CCR7 receptor, could block CCL21 effects on microglia and prevent neurodegeneration and behavioral deficits in two mouse models of PD induced with either α-synuclein oligomers (αSynO) or 3,4-dihydroxyphenylacetaldehyde (DOPAL). Altogether, our data indicate that navarixin blocks CCL21/CCR7-mediated neuron-microglia communication and could be used as a therapeutic strategy against PD. DOPAL treatment induces neurodegeneration both in vitro and in vivo and triggers PD-like behavior in mice. CCL21 is overexpressed in PD patients and DOPAL-induced mouse model. CCL21-CCR7 mediates microglial cell activation and neuroinflammation in mice. Navarixin inhibits the activation of CCR7 by CCL21 in microglial cells, thereby inducing neuroprotection both in vitro and in vivo and preventing PD-like behavioral deficits in mice.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- H2020 European Research Council (834161)
- Instituto Nacional de Neurociência Translacional
- Programa de Pós-Graduação em Ciências Morfológicas
- Coopération Universitaire et Scientifique avec le Brésil
This publication has 118 references indexed in Scilit:
- CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastomaCellular and Molecular Life Sciences, 2023
- Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesisArthritis & Rheumatism, 2012
- Neuropsychiatric symptoms in Parkinson's diseaseMovement Disorders, 2009
- Association of olfactory dysfunction with risk for future Parkinson's diseaseAnnals of Neurology, 2008
- Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamineActa Neuropathologica, 2007
- Challenge with innate and protein antigens induces CCR7 expression by microglia in vitro and in vivoGlia, 2006
- Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigraActa Neuropathologica, 2006
- Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosisActa Neuropathologica, 2006
- Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degenerationJournal of Neural Transmission, 2004
- Dynamics of microglial activation: A confocal time-lapse analysis in hippocampal slicesGlia, 2001